Annals of Oncology
Papers 10000
1 page of 1,000 pages (10k results)
#1Ludovic EvesqueH-Index: 5
#2Eric FrancoisH-Index: 34
Last. Gérard MilanoH-Index: 45
view all 3 authors...
1 CitationsSource
#1Karolin BehringerH-Index: 19
#2Indra ThielenH-Index: 7
Last. Katrin S. ReinersH-Index: 20
view all 17 authors...
#1D. Roda (ISCIII: Carlos III Health Institute)
#2Susana Roselló (University of Valencia)H-Index: 18
Last. Andrés Cervantes (University of Valencia)H-Index: 56
view all 4 authors...
#1M. Solans (University of Girona)
#2D. S. M. Chan (Imperial College London)H-Index: 13
Last. Dora RomagueraH-Index: 48
view all 5 authors...
#1Yasuhiro Nakamura (Saitama Medical University)H-Index: 15
#2Kenjiro NamikawaH-Index: 10
Last. Hisashi Uhara (Sapporo Medical University)H-Index: 4
view all 22 authors...
Abstract Background Acral melanoma (AM) is an epidemiologically and molecularly distinct entity that is underrepresented in clinical trials on immunotherapy in melanoma. We aimed to analyze the real-world efficacy of anti-PD-1 antibodies in advanced AM. Patients and methods We retrospectively evaluated unresectable stage III or stage IV AM patients treated with an anti-PD-1 antibody in any line at 21 Japanese institutions between 2014 and 2018. The clinicobiologic characteristics, objective resp...
#1Gianluca Mauri (University of Milan)H-Index: 4
#2Sabrina Arena (UNITO: University of Turin)H-Index: 22
Last. Andrea Sartore-Bianchi (University of Milan)H-Index: 41
view all 5 authors...
Abstract Background Colorectal cancer (CRC) represents a major cause of cancer deaths worldwide. Although significant progress has been made by molecular and immune therapeutic approaches, prognosis of advanced stage disease is still dismal. Alterations in the DNA damage response (DDR) pathways are emerging as novel targets for treatment across different cancer types. However, even though preclinical studies have shown the potential exploitation of DDR alterations in CRC, systematic and comprehe...
#1Victor MorenoH-Index: 62
Last. J. De Alvaro (BMS: Bristol-Myers Squibb)
view all 19 authors...
Abstract Background Bromodomain and extra-terminal (BET) proteins are epigenetic readers that regulate expression of genes involved in oncogenesis. CC-90010 is a novel, oral, reversible, small-molecule BET inhibitor. Patients and methods CC-90010-ST-001 (NCT03220347; 2015-004371-79) is a phase I dose-escalation and expansion study of CC-90010 in patients with advanced or unresectable solid tumors and relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL). We report results from the dose escalation...
#1Giuseppe Lamberti (Harvard University)H-Index: 3
#1G. Lamberti (Harvard University)H-Index: 1
Last. Andrew D. Cherniack (Harvard University)H-Index: 57
view all 11 authors...
INTRODUCTION: Programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) is the primary clinically-available biomarker of response to immunotherapy in non-small cell lung cancer (NSCLC), but factors associated with PD-L1 expression are not well understood. METHODS: Consecutive nonsquamous NSCLCs with successful PD-L1 assessment and targeted next-generation sequencing (NGS) were included in this retrospective study. Clinicopathological characteristics, gene mutations, and copy number cha...
#1Jill C. Rubinstein (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 7
#2Norman G. Nicolson (Yale University)H-Index: 3
Last. Emily R. Christison-Lagay (Yale University)H-Index: 6
view all 7 authors...
Abstract Background The term germline is commonly used to refer to any non-tumor control sample analyzed in tumor-normal paired sequencing experiments. Blood is the most commonly utilized control, and variants found in both tumor and blood are considered germline. However, somatic variants accumulate within an organism from embryogenesis throughout life. The resultant mosaicism is extensive and calls into question the assumption that blood, or any somatic tissue, represents the germline. Misclas...
1 CitationsSource
Top fields of study
General surgery